Pharming Group N.V.
PHARHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe,. At a $792.7M market cap, Pharming Group N.V. ranks as a small-cap company within healthcare. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Market Cap
$792.7M
Beta
0.07
P/E (TTM)
86.15
P/E (Fwd)
29.09
EPS (TTM)
$0.13
EPS (Fwd)
$0.39
ROE
3.6%
ROA
3.5%
Cash
$158.3M
Total Debt
$113.3M
Free CF
$37.7M
52W Change
-16.0%
Annual Financials
Cash vs Debt
Where PHAR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PHAR finished 30.14% below its 150-day moving average ($13.04) and 35.25% below its 200-day moving average ($14.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHAR overbought or oversold?
At the October 20, 2026 close, PHAR's RSI(14) was 26.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $158.3M in cash and $113.3M in debt, PHAR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $37.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 3.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $205.6M (2022) to $376.1M (2025), reflecting a 83% increase over the period.
With a beta below 0.7, Pharming Group N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. At over 50x earnings, PHAR carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pharming Group N.V. and its sector.